Le Lézard
Classified in: Health
Subject: RCL

Public Advisory - Equate (lemon flavour), Personnelle (lemon flavour) and Life Brand (lemon and cherry flavours) Magnesium citrate oral solution saline laxatives recalled due to potential microbial contamination


OTTAWA, ON, July 24, 2022 /CNW/ -

Summary
Product Image(s):

Equate Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

Equate Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour (CNW Group/Health Canada)

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour (CNW Group/Health Canada)

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, cherry flavour

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, cherry flavour (CNW Group/Health Canada)

Personnelle Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

Personnelle Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour (CNW Group/Health Canada)

Affected products

Product

NPN

Lot

Equate Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

80015316

All lots

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

80015316

All lots

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, cherry flavour

80015316

All lots

Personnelle Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

80015316

All lots

Issue

Health Canada is advising that all lots of Equate (lemon flavour), Life Brand (lemon and cherry flavours) and Personnelle (lemon flavour) Magnesium citrate oral solution saline laxative (NPN 80015316) are being recalled by the importer, Shandex Sales Group Ltd. (Shandex Group), due to the possibility of microbial contamination. The company is recalling the products as a precaution in light of a recall in the United States (U.S.) of similar products that are manufactured at the same site.

Magnesium citrate oral solution is used as a laxative for relief of occasional constipation. The product is indicated for use in adults and children two years of age and older.

Microbial testing of the products recalled in the U.S. identified the presence of Gluconacetobacter liquefaciens. Ingesting contaminated product may result in symptoms including abdominal discomfort or pain, diarrhea, nausea and vomiting. Children, pregnant women, the elderly and people with a weakened immune system may be more susceptible to serious adverse effects from microbial contamination.

The Department is monitoring the company's recall and will inform Canadians if any new health risks are identified.

What you should do

Alert / recall type: Public Advisory
Category: Health products ? Natural health products
Published by: Health Canada

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 13:26
In a bid to foster excellence and innovation in the healthcare industry, the esteemed Dr. Vidal Sheen proudly announces the launch of The Dr. Vidal Sheen Grant for Healthcare Students. With a robust focus on academic prowess, compassionate care, and...

at 13:17
Rexall is proud to unveil its first Pharmacist Care Walk-In Clinic in Barrie, Ontario on Friday, April 19. Located at 353 Duckworth Street, the clinic will offer personalized care to the community while providing immediate pharmacist treatment for...

at 13:13
Caring for communities extends beyond life-changing work in operating rooms and physician offices. Hartford HealthCare leadership today highlighted its corporate responsibility to environmental, social and economic sustainability in announcing its...

at 13:04
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

at 12:30
The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best...

at 12:10
Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's...



News published on and distributed by: